Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | LIPE | Q05469 | 3/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451982 | 0.86 | MAPK14 (0.44) | ACHELIPEMAPK14BCHEMAPK10 | |
| SCHEMBL14033094 | 0.70 | MAPK14 (0.58) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL4085388 | 0.68 | CNR1 (0.67) | CNR1 | |
| SCHEMBL11016914 | 0.66 | KMT2A (0.43) | MAPK14ALDH1A1MAPK13MAPK12MAPK11 | |
| SCHEMBL11622732 | 0.64 | ACHE (0.41) | ACHELIPEBCHEALDH1A1 | |
| SCHEMBL5104394 | 0.64 | MAPK14 (0.66) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL11621698 | 0.63 | CCNC (0.41) | ACHELIPEBCHEALDH1A1CYP1A2 | |
| SCHEMBL31582403 | 0.63 | ALDH1A1 (0.58) | ALDH1A1 | |
| SCHEMBL4085484 | 0.63 | CNR1 (1.00) | CNR1 | |
| SCHEMBL4076019 | 0.62 | CNR1 (1.00) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185169-A1 | 2-Mercapto-4,5-Diarylimidazole Derivatives and the use thereof as Cyclooxygenase Inhibitors | BEIERSDORF, AG | 2007-08-09 | — | — | US | disclosed |
| US-7223781-B2 | 2-mercapto-4,5-diarylimidazole derivatives and the use thereof as cyclooxygenase inhibitors | BEIERSDORF AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20040116695-A1 | 2-Mercapto-4,5-diarylimidazole derivatives and the use thereof as cyclooxygenase inhibitors | BEIERSDORF AG (DE) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185169-A1 | 2-Mercapto-4,5-Diarylimidazole Derivatives and the use thereof as Cyclooxygenase Inhibitors | PTGS2, PTGES2, DHFR | CNR1 2128/4885ACHE 1428/4885LIPE 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.